Robert Griffin
Concepts (701)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 37 | 2024 | 1249 | 5.290 |
Why?
| Hyperthermia, Induced | 17 | 2019 | 117 | 3.730 |
Why?
| Mammary Neoplasms, Experimental | 12 | 2015 | 121 | 3.360 |
Why?
| Radiotherapy | 10 | 2021 | 127 | 3.060 |
Why?
| Gold | 9 | 2023 | 136 | 2.640 |
Why?
| Bystander Effect | 5 | 2024 | 26 | 2.160 |
Why?
| Air Pollutants | 12 | 2023 | 60 | 2.110 |
Why?
| Radiation-Sensitizing Agents | 11 | 2023 | 53 | 2.110 |
Why?
| Mice | 74 | 2024 | 5759 | 2.100 |
Why?
| Animals | 99 | 2024 | 13246 | 2.030 |
Why?
| Nanostructures | 5 | 2023 | 47 | 1.890 |
Why?
| Cell Line, Tumor | 39 | 2024 | 1416 | 1.770 |
Why?
| Exosomes | 7 | 2022 | 50 | 1.720 |
Why?
| Angiogenesis Inhibitors | 8 | 2017 | 188 | 1.610 |
Why?
| Phototherapy | 5 | 2022 | 45 | 1.600 |
Why?
| Radiation Tolerance | 9 | 2020 | 85 | 1.560 |
Why?
| Metal Nanoparticles | 4 | 2023 | 85 | 1.520 |
Why?
| Blood Vessels | 9 | 2020 | 71 | 1.520 |
Why?
| Nanoparticles | 6 | 2022 | 152 | 1.490 |
Why?
| Neoplasms, Experimental | 6 | 2020 | 114 | 1.460 |
Why?
| Galectin 1 | 4 | 2017 | 21 | 1.430 |
Why?
| Aerosols | 10 | 2023 | 73 | 1.410 |
Why?
| Lung Neoplasms | 9 | 2024 | 605 | 1.400 |
Why?
| Oxygen | 12 | 2020 | 325 | 1.370 |
Why?
| Polyethylene Glycols | 4 | 2022 | 93 | 1.330 |
Why?
| Carcinoma, Squamous Cell | 6 | 2019 | 318 | 1.270 |
Why?
| Combined Modality Therapy | 17 | 2022 | 636 | 1.150 |
Why?
| Endothelial Cells | 7 | 2021 | 270 | 1.130 |
Why?
| Humans | 106 | 2024 | 50208 | 1.100 |
Why?
| Tumor Necrosis Factor-alpha | 8 | 2019 | 388 | 1.060 |
Why?
| Sulfates | 2 | 2023 | 25 | 1.040 |
Why?
| Fibrosarcoma | 7 | 2019 | 15 | 1.030 |
Why?
| Neovascularization, Pathologic | 9 | 2021 | 162 | 1.020 |
Why?
| Apoptosis | 10 | 2024 | 1112 | 1.000 |
Why?
| Antineoplastic Agents | 13 | 2024 | 1186 | 0.950 |
Why?
| Liposomes | 2 | 2022 | 53 | 0.940 |
Why?
| Oxygen Consumption | 4 | 2020 | 188 | 0.930 |
Why?
| Peptides | 10 | 2022 | 223 | 0.920 |
Why?
| Ozone | 6 | 2022 | 19 | 0.910 |
Why?
| Benzeneacetamides | 2 | 2024 | 13 | 0.890 |
Why?
| Glutaminase | 2 | 2024 | 19 | 0.890 |
Why?
| Cell Communication | 3 | 2021 | 69 | 0.880 |
Why?
| Fluorescent Dyes | 5 | 2022 | 106 | 0.880 |
Why?
| Mice, Inbred BALB C | 8 | 2020 | 305 | 0.880 |
Why?
| Proteins | 6 | 2010 | 345 | 0.860 |
Why?
| Indocyanine Green | 2 | 2013 | 34 | 0.820 |
Why?
| Neoplastic Cells, Circulating | 3 | 2017 | 74 | 0.790 |
Why?
| Pyrimidines | 9 | 2024 | 193 | 0.770 |
Why?
| Protein Kinase Inhibitors | 6 | 2024 | 206 | 0.770 |
Why?
| Thiadiazoles | 3 | 2024 | 19 | 0.740 |
Why?
| Cell Survival | 16 | 2024 | 602 | 0.740 |
Why?
| Flow Cytometry | 5 | 2017 | 476 | 0.740 |
Why?
| Radiotherapy, Intensity-Modulated | 4 | 2022 | 174 | 0.720 |
Why?
| Radiosurgery | 6 | 2020 | 118 | 0.720 |
Why?
| Antioxidants | 2 | 2020 | 241 | 0.700 |
Why?
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 154 | 0.690 |
Why?
| Radiation-Protective Agents | 1 | 2020 | 74 | 0.680 |
Why?
| Radiation Dosage | 2 | 2020 | 157 | 0.680 |
Why?
| Immunotherapy | 2 | 2021 | 240 | 0.680 |
Why?
| Radiotherapy Dosage | 6 | 2022 | 246 | 0.670 |
Why?
| Radiotherapy Planning, Computer-Assisted | 6 | 2023 | 250 | 0.660 |
Why?
| Head and Neck Neoplasms | 3 | 2019 | 273 | 0.660 |
Why?
| Models, Theoretical | 7 | 2015 | 174 | 0.660 |
Why?
| Epigenesis, Genetic | 2 | 2019 | 378 | 0.630 |
Why?
| Information Dissemination | 2 | 2016 | 79 | 0.620 |
Why?
| Drug Delivery Systems | 2 | 2022 | 146 | 0.620 |
Why?
| Arsenicals | 3 | 2007 | 14 | 0.620 |
Why?
| Oxides | 3 | 2007 | 18 | 0.610 |
Why?
| Molecular Imaging | 2 | 2015 | 53 | 0.610 |
Why?
| Cell Proliferation | 12 | 2024 | 1013 | 0.600 |
Why?
| Uncertainty | 2 | 2022 | 45 | 0.600 |
Why?
| Xenograft Model Antitumor Assays | 13 | 2021 | 212 | 0.590 |
Why?
| Bone and Bones | 2 | 2012 | 475 | 0.580 |
Why?
| Disease Models, Animal | 11 | 2020 | 1458 | 0.580 |
Why?
| Female | 35 | 2021 | 26635 | 0.580 |
Why?
| Gamma Rays | 2 | 2020 | 49 | 0.580 |
Why?
| Oxidation-Reduction | 5 | 2023 | 320 | 0.580 |
Why?
| Radiotherapy, Conformal | 2 | 2019 | 53 | 0.570 |
Why?
| Pneumonia, Viral | 1 | 2020 | 169 | 0.570 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 121 | 0.560 |
Why?
| Coronavirus Infections | 1 | 2020 | 178 | 0.560 |
Why?
| Science | 1 | 2016 | 17 | 0.560 |
Why?
| Mice, Nude | 12 | 2019 | 254 | 0.560 |
Why?
| Radiobiology | 5 | 2023 | 21 | 0.550 |
Why?
| Mouth Neoplasms | 4 | 2015 | 20 | 0.530 |
Why?
| Pandemics | 1 | 2020 | 562 | 0.500 |
Why?
| Cell Hypoxia | 6 | 2015 | 82 | 0.500 |
Why?
| Environmental Monitoring | 7 | 2023 | 65 | 0.480 |
Why?
| Carcinoma | 2 | 2013 | 139 | 0.480 |
Why?
| Enzyme Inhibitors | 6 | 2018 | 386 | 0.470 |
Why?
| Solanum tuberosum | 1 | 2014 | 5 | 0.470 |
Why?
| Laser Therapy | 2 | 2013 | 84 | 0.470 |
Why?
| Sanitation | 1 | 2014 | 16 | 0.470 |
Why?
| Radiation Oncology | 3 | 2024 | 24 | 0.470 |
Why?
| Bone Marrow Neoplasms | 1 | 2013 | 13 | 0.460 |
Why?
| Coloring Agents | 2 | 2013 | 70 | 0.460 |
Why?
| Aniline Compounds | 5 | 2024 | 43 | 0.460 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 828 | 0.450 |
Why?
| Chemokines | 1 | 2013 | 78 | 0.450 |
Why?
| Spectrum Analysis, Raman | 3 | 2019 | 58 | 0.440 |
Why?
| Infrared Rays | 2 | 2019 | 25 | 0.430 |
Why?
| Tumor Microenvironment | 7 | 2022 | 233 | 0.430 |
Why?
| Tumor Cells, Cultured | 8 | 2019 | 468 | 0.430 |
Why?
| Signal Transduction | 8 | 2021 | 1622 | 0.430 |
Why?
| Indoles | 4 | 2024 | 278 | 0.420 |
Why?
| Adult Stem Cells | 1 | 2012 | 10 | 0.410 |
Why?
| Cell Death | 7 | 2019 | 182 | 0.410 |
Why?
| Antibodies, Monoclonal | 3 | 2020 | 460 | 0.400 |
Why?
| Conservation of Natural Resources | 3 | 2017 | 29 | 0.400 |
Why?
| Lignin | 1 | 2011 | 2 | 0.400 |
Why?
| DNA Damage | 5 | 2019 | 301 | 0.400 |
Why?
| Environmental Pollution | 1 | 2011 | 11 | 0.390 |
Why?
| Bone Neoplasms | 2 | 2011 | 183 | 0.390 |
Why?
| Ecosystem | 3 | 2017 | 64 | 0.390 |
Why?
| Time Factors | 12 | 2017 | 2922 | 0.390 |
Why?
| Mice, Inbred C3H | 9 | 2015 | 83 | 0.380 |
Why?
| Dose-Response Relationship, Radiation | 10 | 2020 | 184 | 0.380 |
Why?
| Models, Biological | 6 | 2018 | 723 | 0.380 |
Why?
| Photochemical Processes | 1 | 2010 | 9 | 0.370 |
Why?
| Photons | 2 | 2020 | 18 | 0.370 |
Why?
| Saliva | 3 | 2007 | 55 | 0.370 |
Why?
| Air Pollution | 2 | 2022 | 42 | 0.370 |
Why?
| Phenols | 1 | 2011 | 80 | 0.370 |
Why?
| Cytokines | 1 | 2013 | 613 | 0.360 |
Why?
| Breast Neoplasms | 6 | 2017 | 1179 | 0.350 |
Why?
| Cell Line | 6 | 2021 | 1021 | 0.350 |
Why?
| Melanoma, Experimental | 2 | 2021 | 45 | 0.350 |
Why?
| Methionine | 3 | 2020 | 135 | 0.350 |
Why?
| Rats | 11 | 2022 | 3299 | 0.340 |
Why?
| Radiation Injuries | 3 | 2020 | 112 | 0.340 |
Why?
| Volatile Organic Compounds | 2 | 2022 | 5 | 0.330 |
Why?
| Particulate Matter | 4 | 2023 | 52 | 0.330 |
Why?
| Hydroxyl Radical | 2 | 2010 | 6 | 0.330 |
Why?
| Glutamine | 3 | 2024 | 171 | 0.330 |
Why?
| Atmosphere | 4 | 2019 | 9 | 0.330 |
Why?
| Receptor, erbB-2 | 5 | 2016 | 74 | 0.320 |
Why?
| Reactive Oxygen Species | 3 | 2024 | 408 | 0.320 |
Why?
| Radiation | 2 | 2020 | 15 | 0.320 |
Why?
| Weightlessness Simulation | 2 | 2020 | 19 | 0.310 |
Why?
| Drug Carriers | 2 | 2013 | 71 | 0.310 |
Why?
| Precancerous Conditions | 2 | 2010 | 83 | 0.310 |
Why?
| History, 20th Century | 3 | 2020 | 99 | 0.310 |
Why?
| Caspase Inhibitors | 1 | 2008 | 16 | 0.310 |
Why?
| Cell Membrane Permeability | 1 | 2008 | 28 | 0.310 |
Why?
| Exons | 3 | 2024 | 95 | 0.300 |
Why?
| China | 3 | 2023 | 88 | 0.300 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 30 | 0.300 |
Why?
| Forecasting | 4 | 2020 | 150 | 0.300 |
Why?
| Nanomedicine | 2 | 2024 | 21 | 0.300 |
Why?
| Male | 20 | 2024 | 25399 | 0.300 |
Why?
| Freezing | 2 | 2004 | 16 | 0.290 |
Why?
| Caspases | 1 | 2007 | 104 | 0.290 |
Why?
| Adenocarcinoma | 1 | 2011 | 397 | 0.290 |
Why?
| Vascular Neoplasms | 1 | 2007 | 17 | 0.280 |
Why?
| Nanotubes, Carbon | 2 | 2017 | 68 | 0.280 |
Why?
| Radiotherapy, Image-Guided | 2 | 2016 | 23 | 0.270 |
Why?
| Texas | 6 | 2022 | 139 | 0.270 |
Why?
| Risk Assessment | 3 | 2017 | 1262 | 0.270 |
Why?
| Glutathione | 2 | 2019 | 296 | 0.270 |
Why?
| Microscopy, Fluorescence | 3 | 2018 | 166 | 0.260 |
Why?
| Cryotherapy | 2 | 2011 | 12 | 0.260 |
Why?
| Melanoma | 2 | 2020 | 290 | 0.260 |
Why?
| Organs at Risk | 3 | 2022 | 70 | 0.250 |
Why?
| Hindlimb | 2 | 2004 | 30 | 0.250 |
Why?
| Hydrogen-Ion Concentration | 5 | 2005 | 176 | 0.250 |
Why?
| Ovarian Neoplasms | 2 | 2008 | 447 | 0.240 |
Why?
| Doxorubicin | 2 | 2024 | 239 | 0.240 |
Why?
| Cell Culture Techniques | 2 | 2019 | 99 | 0.240 |
Why?
| Disease Progression | 4 | 2019 | 831 | 0.240 |
Why?
| Oxidants, Photochemical | 1 | 2004 | 3 | 0.230 |
Why?
| Endocytosis | 1 | 2024 | 63 | 0.230 |
Why?
| Smog | 1 | 2004 | 5 | 0.230 |
Why?
| Biological Availability | 1 | 2024 | 96 | 0.230 |
Why?
| Porphyrins | 1 | 2023 | 11 | 0.230 |
Why?
| Oxidants | 1 | 2004 | 53 | 0.230 |
Why?
| Nitroimidazoles | 2 | 2015 | 15 | 0.230 |
Why?
| Clinical Trials as Topic | 3 | 2023 | 466 | 0.230 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2017 | 202 | 0.230 |
Why?
| Proteomics | 4 | 2021 | 330 | 0.220 |
Why?
| Radiometry | 2 | 2016 | 122 | 0.220 |
Why?
| Photochemotherapy | 1 | 2023 | 34 | 0.220 |
Why?
| Sulfur Oxides | 1 | 2023 | 1 | 0.220 |
Why?
| Gulf of Mexico | 1 | 2023 | 5 | 0.220 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2021 | 117 | 0.220 |
Why?
| Receptor Protein-Tyrosine Kinases | 2 | 2008 | 51 | 0.220 |
Why?
| Carcinoma, Hepatocellular | 2 | 2023 | 193 | 0.220 |
Why?
| Partial Pressure | 3 | 2011 | 14 | 0.220 |
Why?
| Halogens | 1 | 2022 | 4 | 0.210 |
Why?
| Organic Anion Transporters | 1 | 2022 | 1 | 0.210 |
Why?
| Phosphatidylethanolamines | 1 | 2022 | 11 | 0.210 |
Why?
| Environmental Exposure | 2 | 2022 | 199 | 0.210 |
Why?
| Lipid Bilayers | 1 | 2022 | 13 | 0.210 |
Why?
| Tumor Burden | 3 | 2010 | 131 | 0.210 |
Why?
| Bile | 1 | 2022 | 23 | 0.210 |
Why?
| Chloral Hydrate | 1 | 2022 | 19 | 0.210 |
Why?
| Parasites | 1 | 2002 | 3 | 0.210 |
Why?
| Water Pollution | 1 | 2002 | 8 | 0.210 |
Why?
| Tissue Distribution | 1 | 2022 | 163 | 0.210 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.210 |
Why?
| Receptors, Growth Factor | 1 | 2002 | 7 | 0.210 |
Why?
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 6 | 0.210 |
Why?
| Protein Binding | 5 | 2020 | 665 | 0.200 |
Why?
| X-Rays | 3 | 2016 | 55 | 0.200 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 3 | 2007 | 13 | 0.200 |
Why?
| Naphthoquinones | 3 | 2007 | 10 | 0.200 |
Why?
| Biological Transport | 2 | 2021 | 172 | 0.200 |
Why?
| Protons | 1 | 2022 | 69 | 0.200 |
Why?
| Cholesterol | 1 | 2022 | 147 | 0.200 |
Why?
| Liver Neoplasms | 2 | 2023 | 328 | 0.200 |
Why?
| Plasmodium falciparum | 1 | 2021 | 18 | 0.200 |
Why?
| Pyrroles | 1 | 2002 | 69 | 0.200 |
Why?
| Boron Compounds | 1 | 2021 | 19 | 0.200 |
Why?
| Malaria, Falciparum | 1 | 2021 | 13 | 0.200 |
Why?
| Floods | 1 | 2021 | 2 | 0.200 |
Why?
| Nucleotides, Cyclic | 1 | 2021 | 4 | 0.190 |
Why?
| Neoplasm Proteins | 3 | 2017 | 324 | 0.190 |
Why?
| Spheroids, Cellular | 3 | 2019 | 25 | 0.190 |
Why?
| High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.190 |
Why?
| Optical Imaging | 2 | 2020 | 25 | 0.190 |
Why?
| Endosomes | 1 | 2021 | 33 | 0.190 |
Why?
| Administration, Oral | 5 | 2024 | 434 | 0.190 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2021 | 21 | 0.190 |
Why?
| Radiation, Ionizing | 4 | 2018 | 100 | 0.190 |
Why?
| Cells, Cultured | 4 | 2020 | 1581 | 0.180 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 56 | 0.180 |
Why?
| Proteasome Inhibitors | 1 | 2021 | 104 | 0.180 |
Why?
| Proton Therapy | 1 | 2020 | 11 | 0.180 |
Why?
| Cell Transformation, Neoplastic | 3 | 2018 | 179 | 0.180 |
Why?
| Chronic Pain | 1 | 2023 | 166 | 0.180 |
Why?
| Spectrum Analysis | 1 | 2020 | 71 | 0.180 |
Why?
| Thymus Gland | 1 | 2020 | 41 | 0.180 |
Why?
| History, 21st Century | 1 | 2020 | 55 | 0.180 |
Why?
| Neural Stem Cells | 1 | 2020 | 26 | 0.180 |
Why?
| Cell Differentiation | 2 | 2020 | 650 | 0.180 |
Why?
| Adenosine Triphosphate | 1 | 2021 | 233 | 0.170 |
Why?
| Public Health | 1 | 2002 | 203 | 0.170 |
Why?
| Heavy Ion Radiotherapy | 1 | 2019 | 2 | 0.170 |
Why?
| Receptor, TIE-2 | 2 | 2017 | 16 | 0.170 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 10 | 0.170 |
Why?
| Calixarenes | 2 | 2017 | 9 | 0.170 |
Why?
| Spleen | 1 | 2020 | 172 | 0.170 |
Why?
| Societies, Medical | 1 | 2020 | 177 | 0.170 |
Why?
| Autoantibodies | 1 | 2020 | 116 | 0.170 |
Why?
| Cone-Beam Computed Tomography | 2 | 2016 | 33 | 0.170 |
Why?
| Whole-Body Irradiation | 1 | 2020 | 131 | 0.170 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 143 | 0.170 |
Why?
| Mutagenesis, Insertional | 3 | 2024 | 24 | 0.170 |
Why?
| Interleukin-6 | 2 | 2020 | 265 | 0.170 |
Why?
| Preservation, Biological | 1 | 2018 | 9 | 0.160 |
Why?
| Drug Evaluation, Preclinical | 3 | 2015 | 143 | 0.160 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 78 | 0.160 |
Why?
| Environmental Pollutants | 1 | 2020 | 91 | 0.160 |
Why?
| Ephrin-B2 | 1 | 2018 | 5 | 0.160 |
Why?
| Membrane Proteins | 1 | 2021 | 353 | 0.160 |
Why?
| Cystic Fibrosis | 1 | 2021 | 149 | 0.160 |
Why?
| Paracrine Communication | 1 | 2018 | 12 | 0.160 |
Why?
| Methionine Adenosyltransferase | 1 | 2018 | 19 | 0.160 |
Why?
| Astrocytes | 1 | 2020 | 146 | 0.160 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 128 | 0.160 |
Why?
| Myocytes, Cardiac | 1 | 2019 | 125 | 0.160 |
Why?
| Treatment Outcome | 5 | 2020 | 5155 | 0.160 |
Why?
| Lipopolysaccharides | 1 | 2019 | 194 | 0.160 |
Why?
| Microinjections | 1 | 2018 | 32 | 0.160 |
Why?
| Biological Assay | 1 | 2018 | 46 | 0.160 |
Why?
| Calibration | 1 | 2018 | 58 | 0.160 |
Why?
| Galectins | 1 | 2018 | 5 | 0.160 |
Why?
| Ubiquitin-Activating Enzymes | 1 | 2018 | 4 | 0.150 |
Why?
| Nucleosides | 1 | 2018 | 5 | 0.150 |
Why?
| Prostatic Neoplasms | 2 | 2013 | 394 | 0.150 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 105 | 0.150 |
Why?
| Indazoles | 1 | 2018 | 46 | 0.150 |
Why?
| Gastrointestinal Tract | 1 | 2019 | 101 | 0.150 |
Why?
| Erythrocyte Membrane | 1 | 2017 | 14 | 0.150 |
Why?
| California | 4 | 2010 | 87 | 0.150 |
Why?
| Oceans and Seas | 1 | 2017 | 24 | 0.150 |
Why?
| Particle Size | 2 | 2024 | 80 | 0.150 |
Why?
| Structure-Activity Relationship | 7 | 2021 | 401 | 0.150 |
Why?
| MicroRNAs | 1 | 2021 | 355 | 0.150 |
Why?
| Scavenger Receptors, Class E | 1 | 2019 | 204 | 0.150 |
Why?
| Histocompatibility Antigens Class II | 1 | 2017 | 36 | 0.150 |
Why?
| Small Molecule Libraries | 1 | 2018 | 68 | 0.150 |
Why?
| Models, Molecular | 4 | 2021 | 341 | 0.150 |
Why?
| Epitope Mapping | 1 | 2017 | 6 | 0.140 |
Why?
| Vehicle Emissions | 1 | 2017 | 10 | 0.140 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 22 | 0.140 |
Why?
| Silver | 1 | 2017 | 47 | 0.140 |
Why?
| Bacteria | 1 | 2018 | 222 | 0.140 |
Why?
| Ammonia | 1 | 2017 | 72 | 0.140 |
Why?
| Pyridazines | 2 | 2008 | 11 | 0.140 |
Why?
| Myocardial Infarction | 1 | 2021 | 396 | 0.140 |
Why?
| Sulfonamides | 1 | 2018 | 128 | 0.140 |
Why?
| Random Allocation | 2 | 2015 | 282 | 0.140 |
Why?
| Biomass | 1 | 2016 | 18 | 0.140 |
Why?
| Epithelial Cells | 1 | 2018 | 207 | 0.140 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 990 | 0.140 |
Why?
| Mice, Inbred Strains | 3 | 2013 | 161 | 0.140 |
Why?
| Antibodies | 1 | 2017 | 154 | 0.140 |
Why?
| Dendritic Cells | 1 | 2017 | 133 | 0.140 |
Why?
| Radiation Protection | 1 | 2016 | 46 | 0.130 |
Why?
| Extraterrestrial Environment | 1 | 2016 | 7 | 0.130 |
Why?
| Neoplasm Transplantation | 2 | 2007 | 85 | 0.130 |
Why?
| Chemistry, Organic | 2 | 2019 | 2 | 0.130 |
Why?
| Cyclonic Storms | 1 | 2015 | 6 | 0.130 |
Why?
| Organ Specificity | 1 | 2016 | 108 | 0.130 |
Why?
| Extracellular Fluid | 1 | 2015 | 14 | 0.130 |
Why?
| Tomography, Spiral Computed | 1 | 2016 | 56 | 0.130 |
Why?
| Microbubbles | 1 | 2015 | 25 | 0.130 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2016 | 90 | 0.130 |
Why?
| Organ Sparing Treatments | 1 | 2016 | 55 | 0.130 |
Why?
| Multiple Myeloma | 1 | 2010 | 2954 | 0.130 |
Why?
| Sulfuric Acids | 1 | 2015 | 8 | 0.130 |
Why?
| Stromal Cells | 1 | 2015 | 72 | 0.130 |
Why?
| Cell Count | 1 | 2015 | 149 | 0.130 |
Why?
| Pressure | 1 | 2015 | 106 | 0.120 |
Why?
| Rabbits | 3 | 2010 | 374 | 0.120 |
Why?
| Biomedical Research | 1 | 2018 | 236 | 0.120 |
Why?
| Necrosis | 3 | 2013 | 178 | 0.120 |
Why?
| Tandem Mass Spectrometry | 3 | 2017 | 231 | 0.120 |
Why?
| Carbon Radioisotopes | 2 | 2024 | 53 | 0.120 |
Why?
| Imaging, Three-Dimensional | 1 | 2015 | 153 | 0.120 |
Why?
| Carbon Dioxide | 2 | 2005 | 94 | 0.120 |
Why?
| Image Processing, Computer-Assisted | 1 | 2016 | 246 | 0.120 |
Why?
| Cisplatin | 2 | 2024 | 278 | 0.120 |
Why?
| Mexico | 1 | 2014 | 36 | 0.120 |
Why?
| Hot Temperature | 3 | 2013 | 205 | 0.120 |
Why?
| Brain | 2 | 2020 | 1328 | 0.120 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2017 | 485 | 0.120 |
Why?
| Contrast Media | 1 | 2015 | 185 | 0.120 |
Why?
| United States | 4 | 2019 | 4874 | 0.120 |
Why?
| Animals, Inbred Strains | 1 | 2013 | 5 | 0.110 |
Why?
| DNA Methylation | 1 | 2018 | 550 | 0.110 |
Why?
| Stress, Psychological | 1 | 2015 | 261 | 0.110 |
Why?
| Nanoconjugates | 1 | 2013 | 1 | 0.110 |
Why?
| Ultrasonography | 1 | 2015 | 437 | 0.110 |
Why?
| Ions | 2 | 2024 | 33 | 0.110 |
Why?
| Food, Genetically Modified | 1 | 2013 | 1 | 0.110 |
Why?
| Food Labeling | 1 | 2013 | 6 | 0.110 |
Why?
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 4 | 0.110 |
Why?
| Societies, Scientific | 1 | 2013 | 14 | 0.110 |
Why?
| Antigen-Presenting Cells | 1 | 2013 | 26 | 0.110 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 181 | 0.110 |
Why?
| Nanospheres | 1 | 2013 | 8 | 0.110 |
Why?
| Nanotechnology | 1 | 2013 | 36 | 0.110 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2013 | 39 | 0.110 |
Why?
| Nutrition Policy | 1 | 2013 | 40 | 0.110 |
Why?
| Gene Expression Profiling | 2 | 2017 | 1037 | 0.110 |
Why?
| Mice, Inbred C57BL | 4 | 2020 | 1819 | 0.100 |
Why?
| Linear Models | 1 | 2013 | 278 | 0.100 |
Why?
| Film Dosimetry | 1 | 2012 | 15 | 0.100 |
Why?
| Blotting, Western | 1 | 2013 | 601 | 0.100 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 595 | 0.100 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 411 | 0.100 |
Why?
| Glucose | 2 | 2011 | 338 | 0.100 |
Why?
| Surface Plasmon Resonance | 3 | 2017 | 22 | 0.100 |
Why?
| RNA, Messenger | 2 | 2013 | 1108 | 0.100 |
Why?
| North Carolina | 2 | 2022 | 52 | 0.100 |
Why?
| Gold Colloid | 2 | 2011 | 2 | 0.100 |
Why?
| Acids | 1 | 2011 | 11 | 0.100 |
Why?
| Isomerism | 1 | 2011 | 21 | 0.100 |
Why?
| Gene Expression Regulation | 3 | 2021 | 979 | 0.100 |
Why?
| Copper | 1 | 2011 | 43 | 0.100 |
Why?
| Feces | 2 | 2024 | 131 | 0.100 |
Why?
| Injections, Intravenous | 1 | 2011 | 143 | 0.100 |
Why?
| Aldehydes | 1 | 2011 | 83 | 0.100 |
Why?
| Immunohistochemistry | 2 | 2020 | 978 | 0.090 |
Why?
| Acenaphthenes | 1 | 2010 | 1 | 0.090 |
Why?
| Nitrogen Oxides | 1 | 2010 | 3 | 0.090 |
Why?
| Drug Screening Assays, Antitumor | 3 | 2024 | 140 | 0.090 |
Why?
| Positron-Emission Tomography | 1 | 2012 | 294 | 0.090 |
Why?
| Middle Aged | 5 | 2024 | 12206 | 0.090 |
Why?
| Myosins | 1 | 2010 | 17 | 0.090 |
Why?
| T-Lymphocytes | 1 | 2013 | 339 | 0.090 |
Why?
| Bone Transplantation | 1 | 2010 | 47 | 0.090 |
Why?
| Isoxazoles | 1 | 2009 | 14 | 0.090 |
Why?
| Nitrous Acid | 1 | 2009 | 1 | 0.090 |
Why?
| Free Radicals | 1 | 2009 | 28 | 0.090 |
Why?
| Adult | 5 | 2024 | 13324 | 0.090 |
Why?
| Abdomen | 1 | 2010 | 77 | 0.090 |
Why?
| Actins | 1 | 2010 | 119 | 0.090 |
Why?
| Acetylcysteine | 1 | 2010 | 100 | 0.090 |
Why?
| Microcirculation | 1 | 2010 | 71 | 0.090 |
Why?
| Protein Transport | 1 | 2010 | 183 | 0.090 |
Why?
| Formaldehyde | 1 | 2009 | 52 | 0.090 |
Why?
| Naphthalenes | 1 | 2010 | 121 | 0.090 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2009 | 53 | 0.080 |
Why?
| Glycolysis | 2 | 2021 | 70 | 0.080 |
Why?
| Chemotherapy, Adjuvant | 2 | 2016 | 120 | 0.080 |
Why?
| Coculture Techniques | 2 | 2020 | 146 | 0.080 |
Why?
| Prospective Studies | 3 | 2023 | 2379 | 0.080 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2009 | 38 | 0.080 |
Why?
| Glycogen Synthase Kinase 3 | 2 | 2008 | 20 | 0.080 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2008 | 11 | 0.080 |
Why?
| Growth Inhibitors | 2 | 2009 | 27 | 0.080 |
Why?
| Methotrexate | 1 | 2009 | 69 | 0.080 |
Why?
| Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 27 | 0.080 |
Why?
| STAT3 Transcription Factor | 2 | 2020 | 81 | 0.080 |
Why?
| Nerve Tissue Proteins | 2 | 2020 | 193 | 0.080 |
Why?
| Drinking | 2 | 2020 | 38 | 0.080 |
Why?
| Up-Regulation | 2 | 2007 | 453 | 0.080 |
Why?
| Insulin-Like Growth Factor I | 1 | 2009 | 138 | 0.080 |
Why?
| Alkynes | 1 | 2008 | 5 | 0.080 |
Why?
| Cytotoxins | 1 | 2008 | 16 | 0.080 |
Why?
| Regional Blood Flow | 2 | 2005 | 108 | 0.080 |
Why?
| HEK293 Cells | 2 | 2020 | 224 | 0.080 |
Why?
| Cryosurgery | 2 | 2011 | 36 | 0.080 |
Why?
| Chemical Fractionation | 1 | 2007 | 17 | 0.080 |
Why?
| Drug Synergism | 2 | 2005 | 151 | 0.080 |
Why?
| Fluorescence | 2 | 2018 | 41 | 0.070 |
Why?
| Toxicity Tests | 1 | 2008 | 54 | 0.070 |
Why?
| Pyrrolidines | 1 | 2008 | 83 | 0.070 |
Why?
| Oxidative Stress | 1 | 2012 | 771 | 0.070 |
Why?
| Skin | 2 | 2009 | 415 | 0.070 |
Why?
| Cost-Benefit Analysis | 2 | 2021 | 273 | 0.070 |
Why?
| Computer Simulation | 3 | 2016 | 280 | 0.070 |
Why?
| Enzyme Activation | 2 | 2005 | 275 | 0.070 |
Why?
| In Situ Nick-End Labeling | 2 | 2004 | 57 | 0.070 |
Why?
| Hearing Loss, Sensorineural | 1 | 2008 | 75 | 0.070 |
Why?
| Sesquiterpenes | 1 | 2008 | 89 | 0.070 |
Why?
| Sulfides | 2 | 2018 | 28 | 0.070 |
Why?
| Histones | 2 | 2020 | 313 | 0.070 |
Why?
| Angiopoietin-2 | 2 | 2017 | 15 | 0.070 |
Why?
| Angiopoietin-1 | 2 | 2017 | 16 | 0.070 |
Why?
| Neurons | 2 | 2020 | 460 | 0.070 |
Why?
| Concept Formation | 1 | 2006 | 12 | 0.070 |
Why?
| Fibroblast Growth Factor 2 | 2 | 2017 | 34 | 0.070 |
Why?
| Interleukin-2 | 1 | 2006 | 72 | 0.070 |
Why?
| Interleukin-8 | 1 | 2006 | 86 | 0.070 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2017 | 89 | 0.070 |
Why?
| Lasers | 2 | 2019 | 123 | 0.070 |
Why?
| Temperature | 3 | 2018 | 168 | 0.070 |
Why?
| Mice, SCID | 2 | 2021 | 176 | 0.070 |
Why?
| Sarcoma | 1 | 2007 | 67 | 0.070 |
Why?
| Mice, Inbred A | 2 | 2003 | 15 | 0.070 |
Why?
| Feasibility Studies | 2 | 2022 | 380 | 0.070 |
Why?
| Electrophoresis | 1 | 2005 | 16 | 0.070 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 863 | 0.060 |
Why?
| Colorectal Neoplasms | 2 | 2006 | 236 | 0.060 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 225 | 0.060 |
Why?
| Neoadjuvant Therapy | 2 | 2017 | 117 | 0.060 |
Why?
| Carbon | 1 | 2005 | 54 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2006 | 128 | 0.060 |
Why?
| Alkanes | 1 | 2005 | 9 | 0.060 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 60 | 0.060 |
Why?
| Neoplasm Staging | 2 | 2019 | 738 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 138 | 0.060 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 72 | 0.060 |
Why?
| Niacinamide | 1 | 2005 | 22 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2006 | 166 | 0.060 |
Why?
| Transplantation, Heterologous | 2 | 2021 | 75 | 0.060 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 613 | 0.060 |
Why?
| Young Adult | 2 | 2024 | 3981 | 0.060 |
Why?
| Organelles | 1 | 2024 | 20 | 0.060 |
Why?
| Administration, Inhalation | 1 | 2005 | 108 | 0.060 |
Why?
| Rats, Inbred F344 | 1 | 2005 | 196 | 0.060 |
Why?
| Kidney Diseases | 1 | 2007 | 214 | 0.060 |
Why?
| Amines | 1 | 2004 | 41 | 0.060 |
Why?
| MCF-7 Cells | 1 | 2024 | 69 | 0.060 |
Why?
| Lichen Planus, Oral | 1 | 2004 | 1 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 4 | 2009 | 1378 | 0.060 |
Why?
| Leukoplakia, Oral | 1 | 2004 | 6 | 0.060 |
Why?
| Materials Testing | 1 | 2024 | 58 | 0.060 |
Why?
| Drug Combinations | 2 | 2018 | 126 | 0.060 |
Why?
| Photochemistry | 1 | 2004 | 16 | 0.060 |
Why?
| Wind | 1 | 2004 | 5 | 0.060 |
Why?
| Hydrocarbons | 1 | 2004 | 5 | 0.060 |
Why?
| Buthionine Sulfoximine | 1 | 2024 | 14 | 0.060 |
Why?
| Photoacoustic Techniques | 2 | 2016 | 72 | 0.060 |
Why?
| Cities | 2 | 2017 | 17 | 0.060 |
Why?
| Binding Sites | 2 | 2021 | 375 | 0.060 |
Why?
| Cations | 1 | 2023 | 10 | 0.060 |
Why?
| Monoterpenes | 1 | 2003 | 3 | 0.060 |
Why?
| Carboplatin | 1 | 2024 | 53 | 0.060 |
Why?
| Biocompatible Materials | 1 | 2024 | 69 | 0.060 |
Why?
| Phosphorylation | 3 | 2017 | 534 | 0.060 |
Why?
| Statistics, Nonparametric | 1 | 2004 | 193 | 0.060 |
Why?
| Photosensitizing Agents | 1 | 2023 | 21 | 0.060 |
Why?
| Multicenter Studies as Topic | 1 | 2023 | 88 | 0.060 |
Why?
| Antibiotics, Antineoplastic | 1 | 2024 | 81 | 0.060 |
Why?
| Organic Chemicals | 1 | 2003 | 14 | 0.060 |
Why?
| Mass Spectrometry | 2 | 2019 | 301 | 0.060 |
Why?
| Sphingomyelin Phosphodiesterase | 1 | 2003 | 10 | 0.060 |
Why?
| Hepatitis B virus | 1 | 2023 | 27 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 32 | 0.060 |
Why?
| Aged | 3 | 2021 | 9405 | 0.060 |
Why?
| Prognosis | 2 | 2009 | 1954 | 0.050 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2004 | 203 | 0.050 |
Why?
| G2 Phase | 1 | 2003 | 13 | 0.050 |
Why?
| Endothelium, Vascular | 1 | 2005 | 254 | 0.050 |
Why?
| DNA-Binding Proteins | 1 | 2006 | 428 | 0.050 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 32 | 0.050 |
Why?
| Quinazolines | 1 | 2003 | 33 | 0.050 |
Why?
| Mammary Neoplasms, Animal | 1 | 2003 | 35 | 0.050 |
Why?
| Anions | 1 | 2022 | 7 | 0.050 |
Why?
| Consensus | 1 | 2023 | 150 | 0.050 |
Why?
| Analysis of Variance | 1 | 2004 | 564 | 0.050 |
Why?
| Interferons | 1 | 2022 | 38 | 0.050 |
Why?
| Acetone | 1 | 2022 | 7 | 0.050 |
Why?
| Rifampin | 1 | 2022 | 62 | 0.050 |
Why?
| Polyphosphates | 1 | 2022 | 2 | 0.050 |
Why?
| Pain Measurement | 1 | 2023 | 240 | 0.050 |
Why?
| Inositol | 1 | 2022 | 19 | 0.050 |
Why?
| Heating | 1 | 2022 | 7 | 0.050 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 22 | 0.050 |
Why?
| Hepatocytes | 1 | 2023 | 182 | 0.050 |
Why?
| Propionates | 1 | 2002 | 23 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2022 | 1185 | 0.050 |
Why?
| Demography | 1 | 2022 | 92 | 0.050 |
Why?
| Pain Management | 1 | 2023 | 162 | 0.050 |
Why?
| Ferrets | 1 | 2021 | 6 | 0.050 |
Why?
| Protein Isoforms | 1 | 2022 | 119 | 0.050 |
Why?
| Estuaries | 1 | 2021 | 1 | 0.050 |
Why?
| San Francisco | 1 | 2021 | 11 | 0.050 |
Why?
| Hydrodynamics | 1 | 2021 | 8 | 0.050 |
Why?
| Bays | 1 | 2021 | 2 | 0.050 |
Why?
| Income | 1 | 2022 | 99 | 0.050 |
Why?
| Drug Resistance, Neoplasm | 1 | 2024 | 314 | 0.050 |
Why?
| Models, Economic | 1 | 2021 | 17 | 0.050 |
Why?
| Catalytic Domain | 1 | 2021 | 57 | 0.050 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 96 | 0.050 |
Why?
| Protein Structure, Tertiary | 2 | 2017 | 253 | 0.050 |
Why?
| Cricetinae | 1 | 2021 | 212 | 0.050 |
Why?
| Analgesics, Opioid | 1 | 2007 | 557 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 295 | 0.050 |
Why?
| Half-Life | 1 | 2021 | 87 | 0.050 |
Why?
| Phosphates | 1 | 2021 | 47 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2021 | 68 | 0.050 |
Why?
| Molecular Docking Simulation | 1 | 2021 | 75 | 0.050 |
Why?
| Bayes Theorem | 1 | 2021 | 109 | 0.050 |
Why?
| Micronucleus Tests | 1 | 2020 | 6 | 0.050 |
Why?
| ROC Curve | 1 | 2021 | 232 | 0.050 |
Why?
| Cell Line, Transformed | 1 | 2021 | 72 | 0.050 |
Why?
| Software | 2 | 2016 | 271 | 0.050 |
Why?
| Catecholamines | 1 | 2020 | 45 | 0.050 |
Why?
| Limbic Encephalitis | 1 | 2020 | 2 | 0.050 |
Why?
| Elastin | 1 | 2020 | 23 | 0.050 |
Why?
| Monte Carlo Method | 1 | 2020 | 85 | 0.050 |
Why?
| Primary Cell Culture | 1 | 2020 | 61 | 0.040 |
Why?
| ADAM Proteins | 1 | 2020 | 20 | 0.040 |
Why?
| Epitopes | 1 | 2020 | 61 | 0.040 |
Why?
| Antiviral Agents | 1 | 2021 | 173 | 0.040 |
Why?
| HeLa Cells | 1 | 2020 | 260 | 0.040 |
Why?
| Autoantigens | 1 | 2020 | 60 | 0.040 |
Why?
| Cytoprotection | 1 | 2019 | 35 | 0.040 |
Why?
| Facility Design and Construction | 1 | 2019 | 3 | 0.040 |
Why?
| Endothelium | 1 | 2019 | 39 | 0.040 |
Why?
| Energy Intake | 1 | 2020 | 165 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 63 | 0.040 |
Why?
| Glioma | 1 | 2020 | 79 | 0.040 |
Why?
| Stress, Physiological | 1 | 2020 | 170 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 55 | 0.040 |
Why?
| Pancreatic Neoplasms | 1 | 2002 | 208 | 0.040 |
Why?
| Swine | 2 | 2011 | 396 | 0.040 |
Why?
| Diffusion Chambers, Culture | 1 | 2018 | 7 | 0.040 |
Why?
| Culture Media, Serum-Free | 1 | 2018 | 15 | 0.040 |
Why?
| Skin Neoplasms | 1 | 2004 | 492 | 0.040 |
Why?
| Culture Media, Conditioned | 1 | 2018 | 48 | 0.040 |
Why?
| Laminin | 1 | 2018 | 18 | 0.040 |
Why?
| Hep G2 Cells | 1 | 2018 | 36 | 0.040 |
Why?
| Specimen Handling | 1 | 2018 | 55 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2004 | 2190 | 0.040 |
Why?
| Program Development | 1 | 2019 | 167 | 0.040 |
Why?
| Flavin-Adenine Dinucleotide | 1 | 2018 | 5 | 0.040 |
Why?
| Dextrans | 1 | 2018 | 18 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2018 | 54 | 0.040 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 35 | 0.040 |
Why?
| NAD | 1 | 2018 | 43 | 0.040 |
Why?
| Surface Properties | 1 | 2018 | 72 | 0.040 |
Why?
| Body Weight | 1 | 2020 | 512 | 0.040 |
Why?
| Proteoglycans | 1 | 2018 | 80 | 0.040 |
Why?
| Autophagy | 1 | 2019 | 169 | 0.040 |
Why?
| Imides | 1 | 2018 | 1 | 0.040 |
Why?
| Hippocampus | 1 | 2020 | 228 | 0.040 |
Why?
| Mid-Atlantic Region | 1 | 2017 | 6 | 0.040 |
Why?
| New England | 1 | 2017 | 10 | 0.040 |
Why?
| Human Activities | 1 | 2017 | 4 | 0.040 |
Why?
| Carbohydrates | 1 | 2018 | 40 | 0.040 |
Why?
| Macaca fascicularis | 1 | 2017 | 10 | 0.040 |
Why?
| Caco-2 Cells | 1 | 2017 | 26 | 0.040 |
Why?
| Ubiquitin | 1 | 2018 | 45 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2018 | 96 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2018 | 111 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2018 | 236 | 0.040 |
Why?
| Cooperative Behavior | 1 | 2019 | 227 | 0.040 |
Why?
| Phagocytosis | 1 | 2017 | 49 | 0.040 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 198 | 0.040 |
Why?
| Cell Movement | 1 | 2018 | 249 | 0.040 |
Why?
| Nanotubes | 1 | 2017 | 27 | 0.040 |
Why?
| Inflammation | 1 | 2021 | 604 | 0.040 |
Why?
| Drug Interactions | 1 | 2017 | 208 | 0.040 |
Why?
| Collagen | 1 | 2018 | 207 | 0.040 |
Why?
| Cohort Studies | 1 | 2021 | 1422 | 0.040 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2017 | 44 | 0.040 |
Why?
| Cricetulus | 1 | 2017 | 108 | 0.040 |
Why?
| Pyrazoles | 1 | 2018 | 114 | 0.040 |
Why?
| Gene Frequency | 1 | 2017 | 94 | 0.040 |
Why?
| CHO Cells | 1 | 2017 | 121 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 381 | 0.040 |
Why?
| Chromatography, Liquid | 1 | 2017 | 225 | 0.030 |
Why?
| DNA Repair | 1 | 2018 | 193 | 0.030 |
Why?
| Fires | 1 | 2016 | 14 | 0.030 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2016 | 9 | 0.030 |
Why?
| Taxoids | 1 | 2016 | 37 | 0.030 |
Why?
| Interleukin-1alpha | 1 | 2016 | 11 | 0.030 |
Why?
| Platelet-Derived Growth Factor | 1 | 2016 | 23 | 0.030 |
Why?
| Diet | 1 | 2020 | 557 | 0.030 |
Why?
| Receptors, Progesterone | 1 | 2016 | 64 | 0.030 |
Why?
| Hindlimb Suspension | 1 | 2016 | 37 | 0.030 |
Why?
| Wetlands | 1 | 2015 | 2 | 0.030 |
Why?
| Regression Analysis | 1 | 2017 | 395 | 0.030 |
Why?
| Particle Accelerators | 1 | 2016 | 50 | 0.030 |
Why?
| Dicumarol | 2 | 2005 | 3 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2016 | 166 | 0.030 |
Why?
| Energy Metabolism | 1 | 2018 | 279 | 0.030 |
Why?
| Ecology | 1 | 2015 | 17 | 0.030 |
Why?
| Receptors, Estrogen | 1 | 2016 | 131 | 0.030 |
Why?
| Carbonic Anhydrases | 1 | 2015 | 3 | 0.030 |
Why?
| Molecular Structure | 2 | 2008 | 296 | 0.030 |
Why?
| Genotype | 1 | 2017 | 534 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2015 | 57 | 0.030 |
Why?
| Sulfur Dioxide | 1 | 2015 | 3 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2016 | 70 | 0.030 |
Why?
| Public Policy | 1 | 2015 | 38 | 0.030 |
Why?
| Norepinephrine | 1 | 2015 | 113 | 0.030 |
Why?
| Models, Animal | 1 | 2016 | 232 | 0.030 |
Why?
| Epinephrine | 1 | 2015 | 96 | 0.030 |
Why?
| Mice, Knockout | 1 | 2017 | 846 | 0.030 |
Why?
| Risk | 1 | 2015 | 324 | 0.030 |
Why?
| Feeding Behavior | 1 | 2016 | 177 | 0.030 |
Why?
| Weight Gain | 1 | 2016 | 239 | 0.030 |
Why?
| Aged, 80 and over | 1 | 2021 | 3154 | 0.030 |
Why?
| Inhibitory Concentration 50 | 2 | 2004 | 75 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 747 | 0.030 |
Why?
| Culture Media | 2 | 2004 | 93 | 0.030 |
Why?
| Glucocorticoids | 1 | 2015 | 226 | 0.030 |
Why?
| Models, Immunological | 1 | 2013 | 8 | 0.030 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 30 | 0.030 |
Why?
| Bone Resorption | 1 | 2016 | 302 | 0.030 |
Why?
| Protein Structure, Secondary | 1 | 2013 | 72 | 0.030 |
Why?
| Decision Making | 1 | 2015 | 267 | 0.030 |
Why?
| Chronic Disease | 1 | 2015 | 571 | 0.030 |
Why?
| DNA Breaks, Double-Stranded | 1 | 2013 | 72 | 0.030 |
Why?
| Light | 1 | 2013 | 71 | 0.030 |
Why?
| Mutation | 1 | 2018 | 1294 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2016 | 1586 | 0.020 |
Why?
| Computer-Aided Design | 1 | 2011 | 21 | 0.020 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2011 | 3 | 0.020 |
Why?
| Equipment Failure Analysis | 1 | 2011 | 46 | 0.020 |
Why?
| Phantoms, Imaging | 1 | 2011 | 121 | 0.020 |
Why?
| Equipment Design | 1 | 2011 | 285 | 0.020 |
Why?
| Volatilization | 1 | 2010 | 4 | 0.020 |
Why?
| Leukocyte Count | 1 | 2010 | 72 | 0.020 |
Why?
| Solvents | 1 | 2010 | 29 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2016 | 765 | 0.020 |
Why?
| Geography | 1 | 2010 | 60 | 0.020 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2009 | 31 | 0.020 |
Why?
| Air | 1 | 2009 | 23 | 0.020 |
Why?
| Amides | 1 | 2009 | 39 | 0.020 |
Why?
| Retrospective Studies | 1 | 2022 | 6134 | 0.020 |
Why?
| Dogs | 1 | 2009 | 185 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 75 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2009 | 20 | 0.020 |
Why?
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 29 | 0.020 |
Why?
| Thermal Conductivity | 1 | 2009 | 7 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| Binding, Competitive | 1 | 2009 | 94 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2010 | 327 | 0.020 |
Why?
| Pharmacokinetics | 1 | 2008 | 16 | 0.020 |
Why?
| Child | 1 | 2021 | 6851 | 0.020 |
Why?
| Models, Statistical | 1 | 2010 | 224 | 0.020 |
Why?
| Guinea Pigs | 1 | 2008 | 75 | 0.020 |
Why?
| Isatin | 1 | 2008 | 1 | 0.020 |
Why?
| Drug Design | 1 | 2009 | 121 | 0.020 |
Why?
| Auditory Threshold | 1 | 2008 | 49 | 0.020 |
Why?
| Bone Marrow | 1 | 2010 | 363 | 0.020 |
Why?
| Weight Loss | 1 | 2010 | 238 | 0.020 |
Why?
| Probability | 1 | 2008 | 164 | 0.020 |
Why?
| Glycosylphosphatidylinositols | 1 | 2007 | 32 | 0.020 |
Why?
| Crystallography, X-Ray | 1 | 2008 | 148 | 0.020 |
Why?
| Recurrence | 1 | 2009 | 662 | 0.020 |
Why?
| Rubidium | 1 | 2006 | 4 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2009 | 951 | 0.020 |
Why?
| Isoelectric Point | 1 | 2005 | 4 | 0.020 |
Why?
| Isoelectric Focusing | 1 | 2005 | 8 | 0.020 |
Why?
| Peptide Mapping | 1 | 2005 | 22 | 0.020 |
Why?
| Caffeine | 1 | 2006 | 66 | 0.020 |
Why?
| Air Movements | 1 | 2005 | 1 | 0.020 |
Why?
| Liver | 1 | 2011 | 1116 | 0.020 |
Why?
| Cell Cycle | 1 | 2006 | 232 | 0.020 |
Why?
| Quality Control | 1 | 2005 | 92 | 0.020 |
Why?
| Tumor Stem Cell Assay | 1 | 2004 | 17 | 0.020 |
Why?
| Bacterial Proteins | 1 | 2007 | 376 | 0.010 |
Why?
| Tennessee | 1 | 2003 | 37 | 0.010 |
Why?
| HL-60 Cells | 1 | 2003 | 18 | 0.010 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2009 | 486 | 0.010 |
Why?
| Solubility | 1 | 2003 | 71 | 0.010 |
Why?
| Cyclin B | 1 | 2003 | 4 | 0.010 |
Why?
| Water | 1 | 2003 | 75 | 0.010 |
Why?
| Cyclin B1 | 1 | 2003 | 5 | 0.010 |
Why?
| CDC2 Protein Kinase | 1 | 2003 | 16 | 0.010 |
Why?
| Heat-Shock Proteins | 1 | 2003 | 106 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2004 | 1541 | 0.010 |
Why?
|
|
Griffin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|